scholarly journals Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients

BMC Cancer ◽  
2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Anne Winther-Larsen ◽  
Ninna Aggerholm-Pedersen ◽  
Birgitte Sandfeld-Paulsen
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Prognostic Markers ◽  
Small Cell ◽  
Added Value ◽  
Inflammation Markers ◽  
Small Cell Lung ◽  
Neutrophil Lymphocyte Ratio ◽  
Lung Cancer Patients ◽  
Lymphocyte Ratio

Abstract Background Inflammation-scores based on general inflammation markers are suggested as prognostic markers of overall survival (OS) in lung cancer. However, whether these inflammation-scores improves the prognostication performed by well-established prognostic markers is unsettled. In a large register-based lung cancer patient cohort, nine different inflammation-scores were compared, and their ability to optimize the prognostication of OS was evaluated. Methods Lung cancer patients diagnosed from 2009–2018 in The Central Denmark Region were identified in the Danish Lung Cancer Registry. Pre-treatment inflammation markers were extracted from the clinical laboratory information system. Prognostication of OS was evaluated by Cox proportional hazard models. Comparison of the inflammation-scores and their added value to established prognostic markers were assessed by Akaike's information criteria and Harrel's C-index. Results In total, 5,320 patients with non-small cell lung cancer (NSCLC) and 890 patients with small cell lung cancer (SCLC) were identified. In NSCLC, the Aarhus composite biomarker score (ACBS), including albumin, C-reactive protein, neutrophil count, lymphocyte count and haemoglobin, and the neutrophil-lymphocyte-ratio (NLR) were superior. Furthermore, they improved the prognostication of OS significantly (p <0.0001) (ACBS: HR: 2.24 (95%CI: 1.97–2.54); NLR: HR: 1.58 (95%CI: 1.47 – 1.69)). In SCLC, three scores were equally superior and improved the prognostication of OS p < 0.0001): neutrophil–lymphocyte-ratio (HR:1.62 (95%CI: 1.38–1.90)), modified Glasgow Prognostic Score (mGPS) (HR:1.70 (95%CI: 1.55–1.86) and the Combined NLR and GPS (CNG) (HR:2.10 (95%CI: 1.77–2.49). Conclusions The ACBS was the optimal score in NSCLC, whereas neutrophil–lymphocyte-ratio, mGPS and CNG were equally superior in SCLC. Additionally, these inflammation-scores all optimised the prognostication of OS and added value to well-established prognostic markers.

The relation between neutrophil lymphocyte ratio and survival in patients with small cell lung cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e18516-e18516
Author(s):  
Mevlude Inanc ◽  
Oktay Bozkurt ◽  
Melih Kiziltepe ◽  
Halit Karaca ◽  
Veli Berk ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Index ◽  
Small Cell ◽  
Small Cell Lung ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
The Relationship

e18516 Background: Neutrophil-lymphocyte ratio (NLR) is not an only inflammation marker, but also used as a prognostic index of various malignancies. Small cell lung cancer (SCLC) is considered metastatic at time of diagnosis, and survival is quite short. There is no any study evaluating the relationship between NLR and survival in SCLC. In this study, we aimed to determine the effect of NLR on overall survival. Methods: The study included 200 patients with SCLC. Survival times of patients, clinicopathological data and the results of a complete blood count at diagnosis were evaluated from patient archive files retrospectively. Patients were randomized into two groups according to NLR 5< or 5≥. Results: The median age of patients was 56 (36-80) years. One hundred and eighty one (90.5%) patients were male and 19 (9.5%) were males. Sixty-eight (34%) patients had dyspnea, 36 (18%) of cases had cough, 22 (11%) patients had back pain, and 14 (7%) of the cases had chest pain. While the duration of symptoms longer than 3 months in 90 (45%) patients, 110 (55%) patients had symptoms shorter than 3 months. Seventy-two (36%) patients had limited disease, 128 (64%) patients had extensive disease at the time of diagnosis. Twenty-one (10.5%) patients had brain metastasis initially. The median neutrophil count was 5.46 (1.02-20.2) 103 µl, and the median lymphocyte 1.69 (0.27 to 21.9) 103 µl, and median NLR was 3.19 (0.04 to 37.63) respectively. NLR overall survival rate was lowering in patients with greater than or equal to 5 group (5 ≥ group=7 months, 5< group=10 months) (p = 0.004). Conclusions: NLR is an important prognostic index that emphasis on the relationship between cancer and host in SCLC. However, a blood test is cheap and easy to use. This study was concluded that survival was shorter in patients with NLR ≥ 5 in SCLC.

Sign in / Sign up

Export Citation Format

Share Document